The synthesis of several bioactive natural products as “privileged scaffolds” for drug discovery will be described. This lecture will also highlight research on the synthesis of peptides, lipopeptides and glycopeptides as a platform for the discovery and development of peptide therapeutics as agents to treat neurogenetic disorders, infectious disease, cancer and diabetes. One example includes the peptidomimetic drug candidate trofinetide (NNZ2566) that has been granted orphan drug status and fast track designation by the US FDA and is currently being evaluated in a final phase III clinical trial undertaken by Neuren Pharmaceuticals Ltd. (see: http://www.neurenpharma.com/IRM/content/default.aspx) to treat Rett Syndrome. The synthetic chemistry that resulted in the founding of the “spin-out” company SapVax with US$5.5 million investment from BioMotiv in Cleveland, Ohio to develop a suite of “first-in-class cancer vaccines” based on a novel self-adjuvanting peptide chemistry platform for immuno-oncology applications (see: https://sapvaxllc.com) will also be described.<br/>

Nature’s medicine chest: Opportunities for synthesis and drug discovery

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.